Xin Lang Cai Jing·2025-12-25 01:52Group 1 - The Haikou Intermediate People's Court ruled in favor of investors in the case against Puli Pharmaceutical, allowing claims for those who purchased shares between April 26, 2022, and April 17, 2024, and sold or held shares after April 17, 2024 [1][2] - Puli Pharmaceutical was found to have overstated its revenue by approximately 514.6 million yuan in 2021, which accounted for 34.11% of the reported revenue for that year, and by about 515.9 million yuan in 2022, representing 28.56% of the reported revenue for that year [1] - The company also overstated its total profit by 308 million yuan in 2021, which was 65.88% of the reported total profit, and by 387.4 million yuan in 2022, which was 88.27% of the reported total profit [1] Group 2 - The law firm representing investors in Puli Pharmaceutical is also pursuing claims against Hainan Huatie, which is currently awaiting court arrangements after multiple submissions for case filing [2] - Hainan Huatie announced the termination of a contract for a computing power service agreement worth 3.69 billion yuan due to significant changes in market conditions since the contract was signed [3] - Investors who bought Hainan Huatie shares between March 5, 2025, and October 1, 2025, and sold or held shares after October 1, 2025, may also initiate claims [3]